PeptiDream Inc. is a Japan-based clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics. The company leverages its proprietary Peptide Discovery Platform to identify constrained peptides with high affinity and specificity against a wide range of biological targets. These therapeutics are designed to modulate protein-protein interactions and engage challenging targets such as G-protein-coupled receptors, intracellular enzymes, and transcription factors.
At the core of PeptiDream’s technology is its Peptide Library and iBody platforms, which allow rapid screening of billions of peptide variants. By integrating advanced chemistry, automation and computational design, the company can generate drug-like peptides with optimized stability, potency and pharmacokinetic properties. This approach has yielded preclinical and clinical candidates across oncology, metabolic and autoimmune disease areas.
PeptiDream has established collaborations with more than 20 leading pharmaceutical companies, including AbbVie, Bristol-Myers Squibb, GlaxoSmithKline and Roche. These partnerships span target discovery, lead optimization and license agreements, providing milestone payments and research fees that support PeptiDream’s own pipeline. Through its global network, the company serves clients in North America, Europe and Asia, and maintains research facilities in Tokyo and Cambridge, Massachusetts.
Founded in 2006 by President & CEO Tetsuro Sasada, PeptiDream combines academic innovation with industry expertise. The management team comprises veterans of drug discovery, peptide chemistry and commercial development. Headquartered in Tokyo, the company remains focused on advancing its internally discovered candidates while delivering peptide-based solutions to pharmaceutical partners worldwide.
AI Generated. May Contain Errors.
Free PPTDF Stock Alerts